Adaptive Biotechnologies Corp — Director's Dealing 2019

Jun 27, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Adaptive Biotechnologies Corp (ADPT)
CIK: 0001478320
Period of Report: 2019-06-26

Reporting Person: ZOLTNERS ANDRIS A (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$0.16	2020-02-24	Common Stock (100000)		Direct
Stock Option (Right to Buy)	$0.84	2024-03-13	Common Stock (20000)		Direct
Stock Option (Right to Buy)	$0.84	2024-03-13	Common Stock (15000)		Direct
Stock Option (Right to Buy)	$6.32	2026-10-18	Common Stock (15000)		Direct
Stock Option (Right to Buy)	$6.55	2028-02-07	Common Stock (15000)		Direct
Stock Option (Right to Buy)	$7.27	2029-02-07	Common Stock (15000)		Direct
Series A Preferred Stock	$0.0		Common Stock (300000)		Direct
Series B Preferred Stock	$0.0		Common Stock (992583)		Direct
Series C Preferred Stock	$0.0		Common Stock (1895806)		Direct
Series E-1 Preferred Stock	$0.0		Common Stock (454545)		Direct
Series F Preferred Stock	$0.0		Common Stock (223082)		Direct

Footnotes

F1: The shares are fully vested and exercisable.

F2: The options vested with respect to 1/12 of such shares on March 7, 2019, with an additional 1/12 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

F3: The shares of preferred stock will convert immediately upon the closing of an initial public offering of the Issuer's common stock on a one-for-one basis and have no expiration date.